Clinical Trial Update: Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC [Phase 2]

View source ↗

Summary

Phase II study evaluating the safety and efficacy of a triple combination of Zimberelimab, Domvanalimab, and Sacituzumab Govitecan as first-line therapy for PD-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Domvanalimab (domvanalimab)
• Sacituzumab Govitecan (sacituzumab govitecan)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: MedSIR | Conditions: Triple Negative Breast Cancer, PDL-1 Positive | Phase 2 | Status: NOT_YET_RECRUITING